Abstract Library

#4537 The usefulness of circulating fibrosis markers in detection of carcinoid heart disease

Introduction: Carcinoid heart disease (CHD) is a potential serious fibrotic complication in patients with neuroendocrine neoplasms (NENs), affecting the heart valves. Early detection is crucial to avoid severe manifestations. NT-proBNP is suggested as an initial screening tool in detection of CHD; however, the value of NT-proBNP as a screening tool is questionable.

Conference:

Presenting Author: Lau T

Authors: Lau T, Angeli E, Oksjoki R, Rasmussen V, Genovese F,

Keywords: carcinoid heart disease, biomarker, fibrosis marker,

#4520 Is late diagnosis and carcinoid heart disease (CaHD) associated with deprivation index? – An audit of practice and assessment of deprivation index in Sheffield ENETS Centre of Excellence

Introduction: Delays to diagnosis in neuroendocrine neoplasms is a world-wide problem. Challenges and inequities recognised include low awareness and access to expert centres. Indices of multiple deprivation (IMD) assess the least to the most deprived areas in the UK, 1 being the most deprived of the 10 deciles.

Conference:

Presenting Author: Munir A

Authors: Abdella O, Abdelhaleem E, Kwok W, Harber J, Rowett O,

Keywords: Index of multiple deprivation, carcinoid syndrome, carcinoid heart disease,

#3980 Interest of serum and urinary 5HIAA, serotonin, chromogranin A and NT-proBNP assays as predictive factors for the development of carcinoid heart disease in neuroendocrine tumors

Introduction: Carcinoid heart disease (CHD) is the main complication of carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs) and has a poor prognosis, with treatment based mainly on high-risk valve replacement surgery.

Conference:

Presenting Author: Walter T

Authors: Lecoeur A, Sfeir R, Damour J, Lombard-Bohas C, Gerard L,

Keywords: neuroendocrine tumors, carcinoid syndrome, carcinoid heart disease, serum 5HIAA, urinary 5HIAA, serotonin, chromogranin A, NT-proBNP,

#3644 N-terminal pro-brain natriuretic peptide and chromogranin A as biomarkers for detection of carcinoid heart disease

Introduction: Carcinoid heart disease (CHD) is a serious complication for patients with neuroendocrine tumors (NETs), and early detection is crucial.

Conference:

Presenting Author: Lau T

Authors: Lau T, Johnson K, Oksjoki R, Baunwall S, Villadsen G,

Keywords: carcinoid heart disease, probnp, 5-hiaa, cga, biomarker,

#3475 Serum Activin A is not associated with carcinoid heart disease (CHD) in patients with neuroendocrine tumors (NET)

Introduction: CHD is a fibrotic cardiac disorder that is caused by serotonin secreted by NET, especially in the presence of liver metastases. Currently, N terminal pro B type natriuretic peptide (NT-proBNP) is used to detect cardiac damage due to CHD, yet no predictive biomarkers are available. Activin A has been identified as a potential biomarker for CHD.

Conference:

Presenting Author: Levy S

Authors: Levy S, Kilgallen A, Korse C, Oerlemans M, Sluijter J,

Keywords: CHD, carcinoid heart disease, biomarker, NT-proBNP, Activin A,